跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-21AI 评分41

Alcon收购Neurotech;Tezspire最新III期临床试验获胜

Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win

AI 导读

瑞士眼科专家Alcon以5.5亿美元首付款收购Neurotech Pharmaceuticals,可能产生额外付款。同时,Tezspire在最新III期临床试验中取得胜利。

正文

Al­con ac­quires Neu­rotech: The Swiss eye spe­cial­ist paid $550 mil­lion up­front to ac­quire Neu­rotech Phar­ma­ceu­ti­cals and could make ad­di­tion­al pay­ments if …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news